There is a version of MoCRA compliance that most importers still operate under, and it goes like this: register the facility, file the product listings, keep the paperwork somewhere retrievable, and the obligation is discharged. That model was defensible in 2024. In 2026 it is out of date, because the listing stopped being a filing and became an input to the decision about whether your container clears.
The shift is not announced in a rule. It shows up in how FDA and Customs and Border Protection now use the data they already have.
The listing is now screening data
Product listings under MoCRA carry the product identity, the ingredient statement and where the product is manufactured. That is precisely the field set an import screening system needs. The practical consequence, flagged repeatedly by trade counsel through 2026, is that incomplete or inaccurate product listings now risk delayed or rejected entries, because FDA and CBP increasingly rely on listing data during random import compliance screening.
Read that carefully, because the failure mode is not the one importers prepare for. The risk is no longer only an enforcement letter arriving weeks later. It is a shipment sitting at the port while somebody tries to reconcile what the listing says against what the manifest says.
As of 6 January 2026, FDA’s system held 14,299 unique active facility registrations and 992,907 unique active product listings. That is a functioning database at national scale. A database that size is not built to be filed into. It is built to be queried against arriving goods.
How much non-compliance is actually out there
The number that should end any argument about whether this matters: a 2024 analysis found that 48 percent of imported cosmetics sold at America’s top 25 retailers were not compliant with MoCRA registration and listing requirements.
Roughly half the imported product on the shelves of the largest retailers in the country, at a point when those retailers had every incentive and every resource to get it right. If that is the compliance rate at the top of the market, the rate among independent importers, distributors and clinics buying direct is not better.
Alongside this, import surveillance has intensified. FDA continues to issue Import Alerts, including the 53-series, targeting heavy metal contamination, undeclared drug ingredients and microbial contamination. Shipments containing non-compliant ingredients are increasingly subject to detention and refusal, and facilities that fail to register or list are facing warning letters and import alerts rather than reminders.
The two curves that are crossing
The enforcement curve is rising. So is the volume curve, and considerably faster.
Korean cosmetics exports reached USD 7 billion in the first half of 2026, up 27.3 percent year on year, the largest first-half total on record. The United States accounted for roughly USD 1.45 billion, about 20.7 percent of the total, up 41.5 percent year on year, holding the number one destination position for a second year. China dropped to about USD 1.01 billion, down 6.6 percent, its share falling from 19.6 percent to 14.4 percent.
A 41.5 percent increase in Korean cosmetics entering the United States, arriving into a screening regime that now reads listing data at the border. Those two lines do not have to cross for long before the detention statistics start moving.
Where importers of Korean product actually fail
The failures are rarely dramatic. They are clerical, and they are the kind that a screening query surfaces instantly.
- The listing does not match the shipped SKU. A brand reformulates, changes a size or renames a variant in Korea, the listing is never updated, and the arriving goods no longer describe what was filed.
- Facility registration lapsed. Registration renews biennially. Korean manufacturers frequently treat this as the U.S. importer’s problem and the U.S. importer assumes the manufacturer handled it. Neither party renews.
- The responsible person is nominal. A name is on the listing, but that entity has no ingredient documentation, no safety substantiation file and no ability to answer an adverse event question about the specific lot.
- Ingredient statements are translated, not reconciled. A Korean ingredient list rendered into English is not the same as an INCI statement that matches the filed listing. Discrepancies here are exactly what a query is designed to catch.
- Nobody owns the file. The single most common structural failure. Sourcing believes compliance handles it, compliance believes the brand handles it, and the brand believes its exporter handles it.
What to do before the next order
None of the fixes are expensive relative to a detained container. All of them are boring.
- Reconcile every active listing against what you are actually importing this quarter, SKU by SKU, including sizes and variant names. Treat a mismatch as a stop-ship, not a to-do.
- Confirm the manufacturing facility registration is current and diarize the biennial renewal in your calendar rather than the manufacturer’s.
- Verify the responsible person can actually perform the role. Ingredient documentation, safety substantiation and an adverse-event process that a human is accountable for.
- Hold the ingredient documentation in English at the lot level, sourced from the manufacturer rather than reconstructed from packaging.
- Name one owner for the compliance file, internally, with the authority to hold a purchase order.
The operator’s view
MoCRA was written as a consumer safety statute and it is being operationalized as a trade control. That is not a criticism, it is just what happens when a regulator gets a complete national database and a border agency that can read it.
For a U.S. clinic, spa or distributor buying Korean product, the practical takeaway is narrow. The compliance file is no longer a document you produce when asked. It is a condition of the goods arriving. Anyone selling you Korean product who cannot show you a current listing, a current facility registration and a real responsible person is selling you a shipment with a hold in its future.
Luxmetics carries this work in-house rather than passing it back to the buyer, which is the entire reason the compliance service exists as a service line and not as a disclaimer. The goal is unremarkable: goods that clear, on the date they were supposed to clear.